Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Non-Small Cell Lung Cancer
Interventions: Gedatolisib, Paclitaxel, Carboplatin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Overweight, Obesity
Interventions: Meditation; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 12 Years to 15 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Normal Non-fluency, Cataract, Aphakic Eye, Eyes With Corneal Abnormality
Interventions: Not listed
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: HIV, Alcoholism
Interventions: Provider Training, Patient Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • Seattle, Washington

Conditions: Healthy, Obese, Overweight, Obesity
Interventions: Orforglipron; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 533 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Anaheim, California • Los Alamitos, California • Daytona Beach, Florida + 4 more

Conditions: Solid Tumor
Interventions: BNT152, BNT153; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: New Haven, Connecticut • Chicago, Illinois • Durham, North Carolina + 3 more

Conditions: Advanced or Metastatic Solid Tumor
Interventions: Rogaratinib (BAY1163877), Copanlisib (BAY80-6946); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions: Hydroxyurea, Acetazolamide; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 7 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: 10 mg of Ketorolac, 15 mg of Ketorolac, 30 mg of Ketorolac; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 64 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Pediatric Obesity, Rural Health, Clinical Practice Guideline
Interventions: Participants: iAmHealthy, Participants: Newsletter; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 6 Years to 11 Years
Enrollment: 1,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Kansas City, Kansas • Omaha, Nebraska • Oklahoma City, Oklahoma + 1 more

Conditions: Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions: Avelumab, Axitinib, Palbociclib; Drug
Lead sponsor: Worldwide Innovative Network Association; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: La Jolla, California • Sioux Falls, South Dakota

Conditions: Type 1 Diabetes Mellitus
Interventions: Psychosocial Survey Questionnaires; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 24 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more

Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 7
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 4 more

Conditions: Solid Tumor
Interventions: 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Prostatic Neoplasms
Interventions: TAK-700; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 19
States / cities: Beverly Hills, California • Los Angeles, California • Aventura, Florida + 8 more

Conditions: Skin Aging
Interventions: Investigational Facial Serum #3, Investigational Facial Serum #1, Investigational Facial Serum #2; Other
Lead sponsor: Victoria Collotta; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Obesity
Interventions: Eating breakfast with portion and unportioned foods; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Healthy
Interventions: GnRH, NAL-GLU GnRH antagonist, Estrogen patch; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sleep Disturbance, Autism Spectrum Disorder
Interventions: Modified Sleep and Circadian Intervention, Enhanced Usual Care; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreatic Cancer
Interventions: TTI-101, Stereotactic body radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Aurora, Colorado • St Louis, Missouri

Conditions: Solid Tumors
Interventions: Oblimersen (Genasense); Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL)
Interventions: AMG 562; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Baltimore, Maryland + 4 more

Conditions: Depressive Disorder
Interventions: Simple Card, Patient Centered Brochure, Physician's endorsement; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)

Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens

Comparative Study of the Optical Biometer for Measurements of the Eye

ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management

iAmHealthy Clinical Practice Guideline (CPG)

Survival Prolongation by Rationale Innovative Genomics

Psychosocial Functioning in Young Adults With Type 1 Diabetes

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Safety Study of TAK-700 in Subjects With Prostate Cancer.

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo

Provision of Breakfast Food in Behavioral Weight Loss

The Effects of Aging and Estrogen on the Pituitary

Community-Engaged Sleep Intervention for School-Aged Children With Autism Spectrum Disorder

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Primary Care Patients With Depression for Internet-Based Social Support